legumain

Legumain inhibitor 1 is a highly potent and specific Legumain inhibitor with potential anticancer activity for cancer research.

RR-11a is a synthetic enzyme legumain inhibitor. This compound specifically targets and inhibits the activity of legumain, an enzyme implicated in various biological processes. RR-11a's synthetic nature allows for precise modulation of legumain activity, making it a valuable tool in biochemical research and potential therapeutic applications.

Esomeprazole is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Esomeprazole is a proton pump inhibitors (PPI).

Legubicin (Doxorubicin-LNAA-Boc) is a conjugate of Doxorubicin linked with a peptide connector hydrolyzable by Legumain. Upon activation by Legumain, Legubicin releases leucine-Doxorubicin, potentially minimizing damage to normal tissues. It inhibits tumor cell growth and reduces DNA binding ability in cells lacking legumain expression. In mice with CT26 tumors, Legubicin completely suppresses tumor growth, making it useful for colon cancer (CRC) research.

Rasagiline-13C3 (mesylate) is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline (mesylate) (T6962) is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo (ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease.

Z-Ala-Ala-Asn-AMC, also known as Cbz-Ala-Ala-Asn-AMC, serves as a substrate for legumain. The overexpression of legumain in 293 HEK-Leg cells results in efficient cleavage of Cbz-Ala-Ala-Asn-AMC.

Esomeprazole-D3 is a deuterated compound of Esomeprazole. Esomeprazole (T20626) has a CAS number of 119141-88-7. Esomeprazole (T20626) is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Esomeprazole (T20626) is a proton pump inhibitors (PPI).